Dewen Leng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dewen Leng has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jin Sun
Department of Pharmacy, Second Military Medical University, Shanghai, China
1 shared publication - Jingsong Huang
Laboratory Medicine, Third Hubei Provincial People’s Hospital, Wuhan, China
1 shared publication - Jun Hu
Department of Physical examination, Wuhan Hospital for Occupational Disease Prevention and Treatment, Wuhan, China
1 shared publication - Qi Yao
Department of Otolaryngology, Wuhan NO. 1 Hospital, Wuhan, China
1 shared publication - Shuo Yang
Wuhan No.1 Hospital
1 shared publication - Xiaolong Huang
Department of Respiratory Medicine, Wuhan No. 1 Hospital, Wuhan, Hubei 430022, P.R. China
1 shared publication
Latest Publications
- Open Access
- 30 August 2017
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 15 (1) , 1-10
Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
Lung cancer stem cells (CSCs) are considered to be the seed of lung cancer, and CD133 is a marker of lung CSCs. Here, we developed gefitinib-loaded poly(ethylene glycol) 2000-distearoylphosphatidylethanolamine nanomicelles with CD133 aptamers (M-Gef-CD133) to eliminate CD133+ lung CSCs. M-Gef-CD133 was prepared using a lipid-film-based approach. The targeting and activity of M-Gef-CD133 towards lung CSCs were evaluated. M-Gef-CD133 were small (25 nm) and showed enhanced cytotoxic effect towards CD133+ lung CSCs compared with non-targeted M-Gef and gefitinib. Notably, M-Gef-CD133 could significantly reduce tumor sphere formation and the percentage of CD133+ lung CSCs, indicating that it possesses selective toxicity against CD133+ lung CSCs. The interaction of CD133 aptamers and CD133 shows promise in the delivery of gefitinib to CD133+ lung CSCs, and M-Gef-CD133 represents a promising treatment to target lung CSCs.
- 30 August 2017
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 15 (1) , 1-10
Open AccessGefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
Lung cancer stem cells (CSCs) are considered to be the seed of lung cancer, and CD133 is a marker of lung CSCs. Here, we developed gefitinib-loaded poly(ethylene glycol) 2000-distearoylphosphatidylethanolamine nanomicelles with CD133 aptamers (M-Gef-CD133) to eliminate CD133+ lung CSCs. M-Gef-CD133 was prepared using a lipid-film-based approach. The targeting and activity of M-Gef-CD133 towards lung CSCs were evaluated. M-Gef-CD133 were small (25 nm) and showed enhanced cytotoxic effect towards CD133+ lung CSCs compared with non-targeted M-Gef and gefitinib. Notably, M-Gef-CD133 could significantly reduce tumor sphere formation and the percentage of CD133+ lung CSCs, indicating that it possesses selective toxicity against CD133+ lung CSCs. The interaction of CD133 aptamers and CD133 shows promise in the delivery of gefitinib to CD133+ lung CSCs, and M-Gef-CD133 represents a promising treatment to target lung CSCs.